The U.S. cannabis market has reached a pivotal moment following the DEA’s April 23, 2026, decision to reschedule marijuana as a Schedule III substance. This classification allows FDA-approved products and state-licensed medical marijuana to be viewed as having moderate to low potential for dependence, significantly altering the regulatory landscape. Green Thumb Industries (GTBIF) is the first company to respond proactively, submitting applications to the DEA to register its operations, signaling a potential shift toward a more normalized federal cannabis industry.
This rescheduling may lead to increased research opportunities and the removal of restrictive tax provisions under Section 280E, which has hindered cannabis operators’ financial performance. Green Thumb’s CEO, Ben Kovler, highlighted the potential for attracting institutional investors, which could significantly boost the company’s stock price. Additionally, the move opens the door for possible future listings on major exchanges, contingent on further regulatory changes.
For investors, Green Thumb’s strategic registration could position it as a frontrunner in the evolving cannabis sector, making it a stock to watch as the industry continues to mature.
Source: fool.com